Torrent Pharma pacts deal with Dr. Reddy's: Signs Agreement for Exclusive Commercialization of its brands, Listril & Listril Plus in Russia

Torrent Pharmaceuticals Ltd on November 29, 2006 has announced that it has concluded an agreement with Dr. Reddy’s Laboratories Ltd. (DRL) for exclusive commercialization of two of the Company's brands in Russia, viz. Listril (Lisinopril) and Listril Plus (Lisinopril HCTZ). Both Listril and Listril Plus are cardiovascular drugs used in the treatment of high blood pressure. The agreement offers the potential for immediate commercialization of these two brands as they have already been registered in Russia.

While the Company will own the registration and trademarks of both the brands, DRL will get exclusive marketing rights to them. The deal provides both the Companies the advantage to strengthen their position in the cardiovascular segment in the Russian market.

This is the second such agreement that the Company has signed with Dr. Reddy's for Russia. The first was for licensing and supplying the formulation of one of its blockbuster drug "Domstal O" (Domperidone + Omeprazole in the Gastro Intestinal segment in July 2004. The Company had licensed the dossier and marketing authorization for the formulation to DRL, which it will soon launch under the brand name Omez D in Ukraine and kazakhstan, followed by Russia and Belarus.

Source : Equity Bulls

Keywords